Comparing a new diabetes pill to metformin
Treatments studied
Part of Hormones & metabolism clinical trials.
This study tests a new medication called TriGlytza-01 against the standard diabetes drug metformin. It is for adults with type 2 diabetes who are overweight or obese and whose blood sugar is not well controlled with metformin alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have type 2 diabetes.
- Your blood sugar is not well controlled even though you take metformin.
- Your body mass index (BMI) is between 25 and 40.
- Your kidneys are working well.
- You are willing to follow study rules and give written consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two different two-drug combinations for people recently diagnosed with type 2 diabetes. It aims to find which combination works better to control blood sugar and improve overall health.
This trial tests a new combination pill (henagliflozin and metformin) compared to metformin alone in people recently diagnosed with type 2 diabetes. The goal is to see which treatment works better and is safer.
This study compares two diabetes pills, imeglimin and metformin, to see which one better improves how your cells process energy and lowers blood sugar in people recently diagnosed with type 2 diabetes. You would take one pill for the study period, and the goal is to find the most effective first treatment for people like you.
This trial tests a combination of three diabetes medicines (dapagliflozin, linagliptin, and metformin) in healthy adults to see how safe they are and how the body processes them. Participating could help make sure these medicines are safe for people with diabetes.
This study tests a new daily pill (QLG1091) against a similar existing pill (Rybelsus) when both are added to your current metformin treatment for type 2 diabetes. The goal is to see if the new pill is as effective and safe for lowering blood sugar.
This trial compares adding a new pill (cofrogliptin) to increasing your current metformin dose, for people whose blood sugar is still too high despite taking an SGLT2 inhibitor and a low dose of metformin. The goal is to see which option works better and is safer.
Hear when a new Type 2 Diabetes (T2DM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.